SEC 13F Intelligence

Managers / Q4 2019

Broadfin Capital, LLC

CIK 0001511901 · 300 PARK AVENUE, 25TH FLOOR, NEW YORK, NY, 10022 · 212-808-2460

Reported Value
$747M
Q4 2019
Positions
40
Filings on Record
5
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Broadfin Capital, Llc reported $747M in U.S.-listed holdings across 40 positions for Q4 2019.

Its largest position, Biodelivery Sciences Intl In, represents 3.6% of the portfolio.

Compared with Q3 2019, the fund opened 11 new positions and exited 15.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $761MQ4 ’18Q1 ’19: $484MQ1 ’19Q2 ’19: $460MQ2 ’19Q3 ’19: $541MQ3 ’19Q4 ’19: $747MQ4 ’19filingsflow.com

Portfolio Composition

By security type
ETP: 41.2%Common Stock: 37.3%Other: 21.6%
  • ETP · 41.2% · $307M
  • Common Stock · 37.3% · $278M
  • Other · 21.6% · $161M

Quarter-over-Quarter Changes full breakdown →

Holdings — Q4 2019

Loading…
#IssuerClass% PortfolioValueShares

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2019$747M40Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$541M44Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$460M39Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$484M43May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$761M50Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Broadfin Healthcare Master Fund Ltd28-14254

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.